Lesinurad (Zurampic)


FDA Approved Indication:
  • Indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone
Prior authorization criteria:
  • Diagnosis of hyperuricemia associated with gout, AND
  • Despite trying and failing first-line agents, patient still has symptomatic hyperuricemia, AND
  • Will be used as combination therapy with a xanthine oxidase inhibitor (i.e., allopurinol or Uloric [febuxostat]), AND
  • Patient does not have any of the following: severe renal impairment (eCLcr < 45 mL/min), end stage renal disease, is a recipient of a kidney transplant, is on dialysis, or has severe (Child-Pugh class C) hepatic impairment, AND
  • Contraindicated for use in tumor lysis syndrome or Lesch-Nyhan syndrome where the rate of uric acid formation is greatly increased
  • 200 mg once daily in combination a xanthine oxidase inhibitor
  • 1 year

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar